0001209191-21-025119.txt : 20210405 0001209191-21-025119.hdr.sgml : 20210405 20210405161027 ACCESSION NUMBER: 0001209191-21-025119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210401 FILED AS OF DATE: 20210405 DATE AS OF CHANGE: 20210405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tessier-Lavigne Marc CENTRAL INDEX KEY: 0001437435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 21805444 MAIL ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-01 0 0001714899 Denali Therapeutics Inc. DNLI 0001437435 Tessier-Lavigne Marc C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2021-04-01 4 S 0 14223 55.606 D 2628073 D Common Stock 2021-04-01 4 S 0 29593 56.906 D 2598480 D Common Stock 2021-04-01 4 S 0 6184 57.595 D 2592296 D The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.22 to $56.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Includes 3,253 restricted stock units. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.23 to $57.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.23 to $58.095 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. /s/ Tyler Nielsen, by power of attorney 2021-04-05